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Abstract 
Objective: Effectiveness has become more and more important as a comprehensive outcome 
measure for (long-term) treatment in schizophrenia. Early predictors to identify patients at a 
high risk for not succeeding the initiated treatment would be very useful. Discontinuation of 
the initiated treatment was used as criterion for effectiveness and patients' drug attitude was 
shown to be predictive for non-adherence or discontinuation of long-term treatment in 
schizophrenia. Accordingly, the predictive validity of the Drug Attitude Inventory (DAI) for 
effectiveness should be evaluated. 
Methods: Based on a sub-sample of patients from the EUFEST study for whom DAI 
assessments were available significant predictors for effectiveness as measured by 
discontinuation of initiated treatment were identified based on a logistic and a Cox-regression 
analysis. A Receiver Operating Characteristic (ROC-) analysis was conducted for the DAI, 
prognostic / diagnostic parameters (sensitivity, specificity) were calculated and a cut-off value 
suggested. 
Results: In a sample of 228 first-episode patients, DAI scores were the most powerful 
predictor for effectiveness (p<0.001) besides two other significant predictors (PANSS-
positive score and sexual side effects). The ROC-analysis revealed an area under the curve of 
0.64 (p<0.001). The suggested cut-off point of about 20 yielded a sensitivity of 70-75% and a 
specificity of 40-45%. 
Conclusions: Study results indicate that the Drug Attitude Inventory, filled in by patients 
early in treatment seems to be a valid predictor for effectiveness as measured by 
discontinuation of the initiated treatment. DAI scores could also serve as a (differential) 
indicator for the need of enhanced treatment monitoring. These findings have to be validated 
in other (first-episode) samples. 
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Introduction 
In recent years, the concept of 'effectiveness' (e.g. Hogarty et al 1997) has become crucial 
regarding the evaluation of long-term drug treatment in schizophrenia (Fleischhacker et al. 
2005, Lieberman et al. 2005, Kahn et al. 2008). As a pragmatic comprehensive measure, it 
integrates aspects of efficacy, safety, and tolerability and considers both, the perspective of 
the patient and the clinician. In general, the rates of retention or (dis-) continuation serve as an 
appropriate indicator reflecting all of these parameters. Since non-adherence or drug 
discontinuation is a critical issue in the long-term treatment of schizophrenia, considerable 
effort has been made to identify early indicators and to provide interventions to keep patients 
in an (in general) effective and safe treatment. Patients' attitude towards drug treatment has 
emerged as one of the factors associated with drug-discontinuation or non-adherence (Lacroet 
al. 2002), so it could be assumed, that it might be a predictor for 'effectiveness' as well. This 
hypothesis was tested by analyzing data from the European First-Episode Schizophrenia Trial 
(EUFEST; Fleischhacker et al. 2005, Kahn et al. 2008). 
In recent years, several studies have identified predictors for treatment discontinuation or non-
adherence in first-episode patients (Verdoux et al. 2000, Kampman et al. 2002, Robinson et 
al. 2002, Mutsatsa et al. 2003, Perkins et al. 2006, De Haan et al. 2007, Perkins et al. 2008, 
Rabinovitch et al. 2009, Miller et al. 2009). The indicators included and extracted are as 
manifold as in multiple episode patients: lower occupational status, substance abuse, 
psychopathology (more pronounced delusional symptoms and suspiciousness; Verdoux et al. 
2000), negative attitudes toward drug treatment and lack of insight (Kampmann et al. 2002, 
Mutsatsa et al. 2003), poor premorbid (cognitive) and post-acute (executive) functioning, 
more pronounced (extrapyramidal) side effects (Robinson et al. 2002, Perkins et al. 2008), 
lower expectations regarding the need for or effectiveness of general or drug-specific 
treatment, treatment with first (vs. second) generation antipsychotics (FGAs / SGAs; Perkins 
et al. 2006), hostility and uncooperativeness, involuntary admission (De Haan et al. 2007), 
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poor treatment response, low adherence to preceding treatment, poor cognitive functioning, 
persisting negative or depressive symptoms, ethnicity (Perkins et al. 2008), less social 
support, living alone, refusing drugs at treatment initiation (Rabinovitch et al. 2009), and 
substance abuse (Perkins et al. 2008, Miller et al. 2009). 
 
Based on theoretical considerations (Perkins 2002, Weiden 2007) and empirical findings, 
patients' attitude towards drug treatment was suggested to be a factor associated with 
treatment discontinuation both in unselected samples (mainly multiple episode patients; Lacro 
et al. 2002) and in first-episode patients (Kampman et al. 2002, Mutsatsa 2003, Perkins et al. 
2006, 2008). Several scales have been developed for an easy and valid assessment of such 
attitudes (e.g. Hogan et al. 1983, McEvoy et al. 1989, Weiden et al. 1994, Kampman et al. 
2000, Dolder et al. 2004). The Drug Attitude Inventory (DAI) by Hogan, Awad and 
colleagues (1983) is one of the earliest developed and most widely used scale. Patients are 
asked to answer 30 dichotomous items (or 10 items in the short form), reflecting various 
positive and negative attitudes to drug treatment. These can be summarized to an overall 
composite score (Hogan et al. 1983). 
 
The main objective of this paper is to examine the predictive validity of the DAI (30 items 
form) regarding effectiveness in first-episode patients, as measured by discontinuation of the 
initiated treatment for any reason. In addition, (other) predictors for effectiveness of long-term 
maintenance treatment in first-episode schizophrenia aimed to be identified. 
 
 
Methods 
Study setting, patients and design 
  
7
The analyzed data derived from EUFEST in which the FGA haloperidol was compared with 
four SGAs (amisulpride, olanzapine, quetiapine, ziprasidone; open randomized design) in 
first-episode patients with schizophrenia spectrum disorders regarding differences in 
effectiveness (i.e. drug discontinuation; see below). Detailed study characteristics have been 
described elsewhere (Fleischhacker et al. 2005, Kahn et al. 2008). A total of 50 centers 
participated in 13 European countries and in Israel. Eligible patients were 18-40 years of age 
and met DSM-IV criteria for schizophrenia, schizophreniform, or schizoaffective disorder 
confirmed by the Mini International Neuropsychiatric Interview Plus (MINI+; Sheehan et al. 
1998). Patients were excluded if: (1) more than two years had passed since the onset of 
positive symptoms; (2) any antipsychotic had been used exceeding two weeks in the previous 
year or six weeks lifetime; (3) patients had a known intolerance to one of the study drugs; (4) 
patients met any of the contraindications for any of the study drugs as mentioned in the (local) 
package insert texts. 
Patients were included after written informed consent was obtained following a complete 
description of the study. The trial complied with the Declaration of Helsinki and was 
approved by the ethics committees of the participating centers. 
Patients were randomized to: haloperidol 1-4 mg/d, amisulpride 200-800 mg/d, olanzapine 5-
20 mg/d, quetiapine 200-750 mg/d, or ziprasidone 40-160 mg/d. All study medications were 
administered orally within the approved dose ranges at the treating physician’s discretion.  
 
Data were collected at baseline (between four weeks before and one week after 
randomization) and after 0.5, 1, 1.5, 2, 3, 6, 9, and 12 months. Assessments included data on 
demographics, diagnosis, psychopathology [PANSS (Kay et al. 1986), CGI (Guy 1976), 
CDSS (Addington et al. 1990)], side effects [St Hans rating scale; SHRS (Gerlach et al. 
1993), UKU-sexual dysfunctions (Scandinavian Society of Psychopharmacology 1987)], 
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quality of life [MANSA (Priebe et al. 1999)], compliance (CRS; Kemp & Hayward 1996), 
and attitude toward drugs (DAI; Hogan et al. 1983). 
 
Effectiveness i.e. discontinuation of the initiated treatment was defined as: (1) the use of a 
dose below the predefined range including complete discontinuation; (2) the use of a dose 
greater than the predefined range (3) the use of another antipsychotic drug—each for more 
than 14 days over 6 months; or (4) the use of any parenteral antipsychotic drug when the drug 
was active for more than 14 days over 6 months. The reason for treatment discontinuation was 
noted. 
 
Statistical methods 
Predictors for effectiveness as the (dichotomous) dependent variable were identified based on 
a logistic and a Cox-regression analysis (including time to discontinuation as the dependent 
variable). Potential predictors initially considered (all assessed at baseline) included: age, 
gender, years of education (years in school following the age of 6), highest degree of 
education (from 1='university completed' to 7='less than high school'), currently employed 
(yes/no), married (yes/no), living alone (yes/no), substance abuse / dependence (yes/no 
according to MINI-plus diagnostic interview), duration of psychosis (months; based on 
interviewers estimate of onset of full syndrome), antipsychotic naïve (yes/no), PANSS-
positive, -negative and -general-score, illness severity (CGI-S), depression (CDSS), akathisia, 
dystonia, parkinsonism and dyskinesia (all 'yes/no' according to SHRS), sexual side effects 
(yes/no according to UKU-sexual dysfunction sub-scale), quality of life (MANSA), 
compliance rating (CRS), and drug attitude (DAI-30). A stepwise forward selection algorithm 
was applied with a 5%-significance limit for inclusion. Since general predictors for 
effectiveness independent of drug treatment should be identified, the drug group was included 
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as a 'strata' variable. Thus, the drug group effects were considered in the model and the 
resulting parameters were adjusted for it. 
 
The prognostic validity of the DAI was assessed with a Receiver-Operating-Characteristic- 
(ROC-) analysis (Hsiao et al. 1989). By varying the cut-off-points of the distribution of the 
DAI-scores, different sensitivity and specificity values were obtained, leading to a specific 
curve. The area under the curve (AUC) was compared with a curve obtained by chance with a 
Wilcoxon statistic. Finally, optimal cut-off-points were discussed. Statistical analyses were 
conducted with SPSS statistical package, version 15. 
 
 
Results 
 
Sample characteristics 
The entire EUFEST sample consisted of 498 patients (haloperidol / hal: n=103 / 20.7%; 
amisulpride / ami: n=104 / 20.9%; olanzapine / ola: n=105 / 21.1%; quetiapine / quet: 104 / 
20.9%; ziprasidone / zipra: n=82 / 16.5%), of whom 232 (46.6%) patients had DAI-
assessments and could be entered into this analyses. Four patients had to be excluded from the 
predictor specific analysis due to missing values in one or more of the parameters. 
Accordingly, the analysis includes n=228 patients (hal: n=43 / 18.9%; ami: n=47 / 20.6%; ola: 
n=53 / 23.2%; quet: 52 / 22.8%; zipra: n=33 / 14.5%). Comparing the entire original sample 
(n=498) with the sample used for this sub-analysis (n=228) yielded no significant differences 
with regard to proportion of drug group assignment, drug group specific discontinuation rates, 
(primary sample: hal=61.2%; ami=30.8%; ola=28.6%; quet=49.0%; zipra=37.8%; predictor 
sample: hal=67.4%; ami=40.4; ola=39.6; quet=53.8; zipra=39.4), gender, age, diagnostic 
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group, prior drug treatment as well as mean PANSS-positive, -negative and -general scores, 
and quality-of-life (MANSA; all p>0.15). 
 
The mean age of the 228 patients was 25.6 years (SD=5.4), and 124 (54.4%) were male. The 
proportion of a diagnosis of schizophrenia, schizophreniform and schizoaffective disorder was 
52.2% (n=119), 40.4% (n=92) and 7.5% (n=17) respectively; 71 (31.1%) of the patients were 
drug-naïve. Treatment discontinuation for any reason was observed in 110 patients (48.2%) 
after a mean of 3.1 months (sd=3.1; median=2.1). 
 
Differences between patients who discontinued and those who completed; identified 
predictors for effectiveness 
At baseline, patients who discontinued differed from those who completed as follows (see 
also Table 1): Patients who discontinued the randomized drug treatment within the 12-month 
observation period had a lower PANSS-positive score (p=0.01) and a lower score on the drug 
attitude inventory (DAI; p<0.001). In addition, the following differences reached borderline 
significance level (0.05<p<0.15): patients who discontinued were younger (p=0.14), had a 
longer illness duration (p=0.08), a lower PANSS-general score (p=0.12), had more akathisia 
(p=0.08) and sexual side effects (p=0.15).  
 
(Insert Table 1 about here) 
 
The logistic regression analysis yielded the following significant predictors based on a 
stepwise forward selection: drug attitude (odds ratio / 'OR' = 0.95; 95%-CI: 0.93; 0.98; 
p<0.001) and PANSS-positive score (OR = 0.91; 95%-CI: 0.86; 0.97; p=0.002). Based on a 
Cox-regression analysis the following predictors for time to discontinuation were selected: 
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drug attitude (hazard ratio / 'HR' = 0.96; 95%-CI: 0.95; 0.98; p<0.001) and sexual side effects 
(according to UKU; HR = 0.63; 95%-CI: 0.42; 0.97; p=0.04). 
 
Prognostic validity of the Drug Attitude Inventory (DAI) 
The ROC-analysis of the Drug Attitude Inventory regarding effectiveness yielded an 
AUC=0.64 which is significantly different from a curve obtained by chance (p<0.001, Figure 
1). 
 
(Insert Figure 1 about here) 
 
Table 2 gives sensitivity and specificity parameters for selected DAI cut-off-points. A low 
cut-off point of <=8 vs. >=10 (patients with scores of 8 and below will be classified / 
predicted as 'discontinued' while 9 and above as 'completed') results in a sensitivity of 42.7% 
(i.e. percentage of patients correctly predicted as discontinued from all patients discontinued) 
and a specificity of 82.2% (i.e. rate of patients correctly predicted as completers from all 
completers). With increasing cut-off scores, sensitivity increases, however specificity 
declines. 
Based on the following considerations, an 'optimal' cut-off point will be suggested: the 
primary aim is to predict / detect patients at high risk for discontinuing the initiated treatment 
(preferred high sensitivity) in order to be able to initiate prophylactic interventions (for 
instance enhanced monitoring or even more specific measures such as compliance 
management). On the other hand 'costs' should be minimized (i.e. not to initiate the 
intervention too often what means that not too many patients overall are below the cut-off-
score) and in particularly to provide the intervention only for those for whom it will be 
indicated (preferred high specificity). In this respect, a DAI cut-off around 20 seems 
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appropriate, resulting in a sensitivity of 70-75%, a specificity of 40-45%, and a rate of 60-
65% from all patients who have a score below the cut-off. 
 
(Insert Table 2 about here) 
 
 
Discussion 
 
Since effectiveness has increasingly been used as an important outcome in schizophrenia, it 
was aimed to investigate the predictive validity of the Drug Attitude Inventory (DAI) in this 
purpose. 
Data derived from the European First Episode Schizophrenia Trial (EUFEST; Fleischhacker 
et al. 2005, Kahn et al. 2008), an open randomized controlled trial comparing four SGAs with 
the FGA haloperidol over one year regarding differences in effectiveness in patients suffering 
from their first psychotic illness episode. 
 
Out of 23 parameters assessed at baseline and included as potential predictors in a logistic and 
a Cox-regression analysis, the patients' attitude toward drugs assessed by the Drug Attitude 
Inventory (DAI) consistently resulted as the strongest predictor for effectiveness (i.e. 
discontinuation of initiated treatment; p<0.001). This corresponds to other studies, in which 
drug attitude was found as a predictor for drug non-adherence or discontinuation in unselected 
samples comprising of mainly multiple episode schizophrenia patients (4) as well as in 
specific samples of first-episode patients (Kampman et al. 2002, Mutsatsa 2003, Perkins et al. 
2006, 2008; in the latter of borderline significance). In the sample analyzed here, only one 
additional significant predictor evolved, depending on the method applied (a lower PANSS-
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positive score in the logistic regression analysis; p=0.002; sexual side effects as measured by 
UKU in the Cox-regression analysis; p=0.04). 
 
In addition, it was aimed to examine the predictive validity of the DAI regarding effectiveness 
(Sackett and Haynes 2002). Therefore, a Receiver-Operating-Characteristic- (ROC-) analysis 
was conducted which yielded an area under the curve (AUC) of 0.64, which is significantly 
different from a curve obtained by chance (p<0.001). This, to our best knowledge, is the first 
time that the predictive validity of the DAI for effectiveness was tested with this method. 
Different values for sensitivity and specificity resulted, depending on DAI cut-off scores. In 
order to predict / detect as many as possible patients at high risk for discontinuation 
sensitivity should be maximized. On the other hand the false-positive rate should be as small 
as possible to ensure that potential measures to prevent treatment discontinuation will not be 
applied to patients who are not in need of it. Thus, we suggest a cut-off-point for the DAI of 
around 20 which would result in a sensitivity of about 70-75% (rate of correctly predicted 
discontinuing patients) and a specificity of about 40-45%. This would entail that in 60-65% of 
all patients, such an intervention would be provided.  
 
Even if there are no other studies regarding predictive / diagnostic validity of predictors for 
effectiveness (or discontinuation; to our best knowledge) to which our results could be 
compared one would expect or wish better parameters. Nevertheless, the DAI is an easy to use 
and valid instrument which provides empirically based support regarding the identification of 
patients at risk to discontinue initiated treatment. In addition, the analyses were conducted in 
one of the largest first episode samples studied in this context, with appreciable numbers of 
antipsychotic-naïve patients. 
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All these results have to be discussed against some limitations. First, a substantial proportion 
of the entire EUFEST sample (about 50%) did not complete the DAI and therefore could not 
be included in this analysis. This might have led to a positive selection of patients with regard 
to the willingness to cooperate and to comply. However, we have compared the total original 
sample and the 'predictor' sample analyzed here regarding various clinical and demographic 
variables (including age, gender, drug assignment, discontinuation rate, diagnosis, duration of 
psychotic illness, pre-treatment, and psychopathology) and no significant differences evolved 
(all significance levels for differences were above 0.15). This might indicate that sample 
selection has not biased results. 
Secondly, generalizability is restricted as identified predictors and parameters have been 
optimized for this sample and need to be validated in independent samples. 
 
 
Conclusions 
Study results indicate that the Drug Attitude Inventory completed by patients early in long-
term treatment appears to be a useful predictor for effectiveness as measured by 
discontinuation of the initiated treatment and could serve as a (differential) indicator to initiate 
specific measures like enhanced monitoring or compliance enhancing interventions. These 
findings have to be validated in other first-episode samples including measures to enhance the 
predictive validity. 
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Table 1: Characteristics of patients, differences between those who completed or discontinued 
initiated drug treatment within the 12-months treatment phase. 
 
 
Total 
(N= 228) 
Completed 
(n= 118) 
Discontinued 
(n= 110) p1 
Age (years; mean; SD) 25.6 5.4 26.1 5.6 25.0 5.2 (0.14) 
Gender (male; N, %) 124 54.4 67 56.8 57 51.8 n.s. 
Years of education (mean, SD) 12.8 2.8 13.0 2.9 12.5 2.7 n.s. 
Highest degree of education (mean, SD) 
(1=univ. compl. to 7= below high school) 4.1 2.0 4.0 2.1 4.1 1.9 n.s. 
Currently employed (N; %) 101 44.3 55 46.6 46 41.8 n.s. 
Married (N; %) 23 10.1 13 11.0 10 9.1 n.s. 
Living alone (N; %) 21 9.2 11 9.3 10 9.1 n.s. 
Substance abuse / dependence (N; %) 
(according to MINI-plus diagnostic interview) 47 20.6 21 17.8 26 23.6 n.s. 
Duration of psychosis (months; mean; SD) 
(based on interviewers estimate of onset of full 
syndrome) 4.2 8.5 3.0 3.4 5.5 11.5 (0.08) 
Antipsychotic naïve (N; %) 71 31.1 37 31.4 34 30.9 n.s. 
PANSS (mean; SD)        
- Positive-score 23.3 5.9 24.3 5.6 22.3 5.9 0.01 
- Negative score 21.1 7.6 21.5 6.8 20.7 8.4 n.s. 
- General-score 44.8 10.3 45.9 10.0 43.7 10.6 (0.12) 
CGI: illness severity (mean; SD) 4.9 0.7 4.9 0.7 5.0 0.8 n.s. 
Depression (CDSS; mean; SD) 5.4 5.2 5.3 5.6 5.4 4.8 n.s. 
Extrapyramidal side effects (SHRS; N; %)        
- Akathisia 21 9.2 7 5.9 14 12.7 (0.08) 
- Dystonia 5 2.2 2 1.7 3 2.7 n.s. 
- Parkinsonism  22 9.6 9 7.6 13 11.8 n.s. 
- Dyskinesia 1 0.4 0 0.0 1 0.9 n.s. 
Sexual side effects (UKU; mean; SD) 59 25.9 26 22.0 33 30.0 (0.15) 
Quality of life (MANSA; mean; SD) 4.0 0.9 4.0 0.9 4.0 0.9 n.s. 
Compliance (CRS; mean; SD) 5.5 1.2 5.6 1.2 5.5 1.2 n.s. 
Drug attitude (DAI; mean; SD) 13.9 11.7 17.0 9.5 10.7 12.9 <0.001 
Randomised study medication (N; %)       0.03 
- Haloperidol 43 18.9 14 11.9 29 26.4  
- Amisulpride 47 20.6 28 23.7 19 17.3  
- Olanzapine 53 23.2 32 27.1 21 19.1  
- Quetiapine 52 22.8 24 20.3 28 25.5  
- Ziprasidone 33 14.5 20 16.9 13 11.8  
1
 Significance level for testing differences between 'Completed' and 'Discontinued'; categorical 
variables: Chi-square-test or Fishers exact test for small cell frequencies; continuous variables: 
Mann-Whitney-Test, since at least one of the pre-conditions for a t-test (homogeneity of variances; 
normal distribution) was not fulfilled; p-values between 0.05 and 0.15 were given in parentheses; 
n.s.: p>0.15. 
Figure 1: ROC-curve of the Drug Attitude Inventory regarding effectiveness / drug discontinuation 
(AUC=0.64; p<0.001) 
 
 
 Table 2: Sensitivity and Specificity regarding effectiveness for different cut-off-points of the Drug 
Attitude Inventory 
Cut-off for DAI1 TP2 Sensitivity3 TN4 Specificity5 % <=Cut-Off6 
<=8 vs. >=10 47 42.7 97 82.2 29.8 
<=10 vs. >=12 47 42.7 92 78.0 32.0 
<=12 vs. >=14 51 46.4 83 70.3 37.7 
<=14 vs. >=16 57 51.8 76 64.4 43.4 
<=16 vs. >=18 66 60.0 63 53.4 53.1 
<=18 vs. >=20 76 69.1 55 46.6 61.0 
<=20 vs. >=22 84 76.4 48 40.7 67.5 
<=22 vs. >=24 88 80.0 35 29.7 75.0 
<=24 vs. >=26 98 89.1 25 21.2 83.8 
1
 The distribution of the DAI-scores (almost exclusively even numbers) results from the scoring 
procedure for the DAI total score  
2
 Frequency 'true positives' ('discontinued' and DAI <= lower cut off) 
3
 Rate (%) of TP from all patients 'discontinued' (N=110) 
4
 Frequency 'true negatives' ('completed' and DAI >= upper cut off) 
5
 Rate (%) of TN from all patients 'completed' (N=118) 
6
 Rate (%) with a DAI-score <= lower cut off from all patients (N=228) 
 
